Anti-Complement Ba [D22/3] Antibody
![Anti-Complement Ba [D22/3] Antibody](https://www.kerafast.com/MediaStorage/Product/Images/Large/1214_2001202001263812130.jpg "Anti-Complement Ba [D22/3] Antibody")
This mouse IgG2b/k monoclonal antibody was generated against a synthetic peptide corresponding to complement fragment Ba and is specific for human complement Ba fragment.
Highlights:
- Reacts with human complement Ba fragment (epitope: Glu215-Arg234)
- Useful as capture antibody in Ba ELISA
- Suitable for Western Blot, ELISA and Flow Cytometry applications
- Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e., specificity) from the hybridoma 9D4.
The complement system consists of a number of small proteins found in the blood, generally synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is massive amplification of the response and activation of the cell-killing membrane attack complex.
From the laboratory of Martin Oppermann, MD, University Medical Center Göttingen.
This mouse IgG2b/k monoclonal antibody was generated against a synthetic peptide corresponding to complement fragment Ba and is specific for human complement Ba fragment.
Highlights:
- Reacts with human complement Ba fragment (epitope: Glu215-Arg234)
- Useful as capture antibody in Ba ELISA
- Suitable for Western Blot, ELISA and Flow Cytometry applications
- Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e., specificity) from the hybridoma 9D4.
The complement system consists of a number of small proteins found in the blood, generally synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is massive amplification of the response and activation of the cell-killing membrane attack complex.
From the laboratory of Martin Oppermann, MD, University Medical Center Göttingen.
| Product Type: | Antibody |
| Antigen: | Ba fragment |
| Accession ID: | P00751 |
| Isotype: | IgG2b/k |
| Clonality: | Monoclonal |
| Clone Name: | D22/3 |
| Reactivity: | Human |
| Immunogen: | synthetic peptide |
| Species Immunized: | Mouse (Balb/c) |
| Epitope: | Neo-Epitopeon Ba (Glu215-Arg234) |
| Buffer: | PBS with 0.02% Proclin 300 |
| Tested Applications: | WB, ELISA, and Flow Cytometry |
| Storage: | -20C |
| Shipped: | Cold packs |
| Clone | Reactivity | Isotype | Epitope | Applications | Functional Properties |
| M20/6 | Human Ba / Factor B | IgG1k | N/A | WB, ELISA, IP | Detecting Ab in Ba ELISA (together with D22/3) |
| D22/3 | Human Ba | IgG2b/k | Neo-Epitope on Ba (Glu215, Arg234) | WB, ELISA, Flow Cytometry | Capture Ab in Ba ELISA (together with M20/6) |
| I3/15 | Human and baboon activated C3 | IgG1k | Neo-Epitope on C3b/iC3b/C3dg | WB, ELISA | Capture Ab in actC3 ELISA (together with rab anti-C3dg) |
| Z22/8 | Porcine C3a/C3a(desArg) | IgG2b/k | Neo-Epitope on C3a/C3a(desArg) | WB, ELISA, IP | Capture Ab in C3a ELISA (together with K5/9); blocks C3a biological activity |
| K5/9 | Porcine C3a/C3a(desArg) | IgG1k | N/A | WB, ELISA | Capture Ab in C3a ELISA (together with Z22/8); blocks C3a biological activity |
| G25/2 | Human and baboon C5/C5a/C5a(desArg) | IgG1k | N/A | WB, ELISA, IP | Detecting Ab in C5a ELISA (together with C17/5); blocks C5a biological activity |
| C17/5 | Human and baboon C5/C5a/C5a(desArg) | IgG1k | Neo-Epitope on C5a/C5a(desArg) | WB, ELISA | Capture Ab in C5a ELISA (together with G25/2); blocks C5a biological activity |
| T13/9 | Porcine C5a/C5a(desArg) | IgG1k | Neo-Epitope on C5a (Tyr57- Gly74) | WB, ELISA, IP | Capture Ab in C5a ELISA (together with rab anti-C5a); blocks C5a biological activity |
- Oppermann, M., Kurts, C., Zierz, R., Quentin, E., Weber, M. H., and Götze, O. (1991) Kidney Int. 40, 939-947
- Oppermann, M., Höpken, U., and Götze, O. (1992) Immunopharm. 24, 119-134
- Oppermann, M. and Götze, O. (1994) Mol. Immunol. 31, 307-314
If you publish research with this product, please let us know so we can cite your paper.
